Wells Fargo raised the firm’s price target on Amgen (AMGN) to $300 from $280 and keeps an Equal Weight rating on the shares. The firm notes the company maintains a positive outlook for several key products and launches, while Amgen looks to manage expenses tightly even with Maritide ramp.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen’s Strong Q3 Performance and Promising Pipeline Justify Buy Rating
- Amgen’s Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating
- Amgen Inc. Reports Strong Q3 2025 Financial Results
- Closing Bell Movers: AMD falls 4% on earnings, Trex, Pinterest down sharply
- Amgen reports Q3 adjusted EPS $5.64, consensus $5.01